Abstract
Heart failure (HF) with low left ventricular ejection fraction (LVEF) is a disease with an unfavorable prognosis, for the treatment of which there is a need to search for drugs that improve patients’ quality of life. Such a group of drugs is inhibitors of sodium-glucose cotransporter type 2 (iSGLT-2). Purpose of the study: to assess the efficacy and safety of the new class of antihyperglycemic drugs — iSGLT-2.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
